Axsome (AXSM) Form 144: 13,390 Shares Proposed Sale

Axsome Therapeutics, Inc. insider filing reports a proposed sale of 13,390 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $1,588,589.60, intended for sale on 10/07/2025.

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. insider filing reports a proposed sale of 13,390 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $1,588,589.60, intended for sale on 10/07/2025. The filing states there are 49,901,487 shares outstanding, and the shares to be sold were acquired on 05/27/2016 as compensation via stock options with a cashless exercise/same-day sale payment.

The notice also discloses multiple insider sales in the prior three months by Herriot Tabuteau: 19,220 shares on 10/06/2025, 27,907 on 09/12/2025, 15,254 on 09/15/2025, and 19,719 on 09/16/2025, totaling 82,100 shares and gross proceeds shown in the filing. The filer affirms no undisclosed material nonpublic information and references Rule 144 procedures.

Positive

• Planned sale documented with broker (Goldman Sachs & Co. LLC) indicating orderly, broker-assisted execution
• Securities were acquired as compensation on 05/27/2016, consistent with ordinary insider liquidity events

Negative

• Substantial recent insider selling: 82,100 shares sold in the past three months, which may increase available float
• No 10b5-1 adoption date provided on the form, leaving uncertainty about reliance on a prearranged trading plan

Insights

Insider Transactions Analyst

Insider selling is ongoing; 13,390 shares planned, 82,100 sold in prior 3 months.

Reported planned sale of 13,390 shares for $1,588,589.60 on 10/07/2025 follows four recent sales totaling 82,100 shares across 09/12/2025–10/06/2025. The shares were originally acquired as compensation on 05/27/2016 and will be sold via a broker, indicating standard liquidity transactions rather than purchases.

Primary dependency is market execution and share count; monitor aggregate insider sales against outstanding 49,901,487 shares for near-term float impact and any further scheduled filings over the next 30 days.

Compliance Counsel

Form 144 disclosure follows Rule 144 mechanics and includes a 10b5-1 attestation clause.

The filing documents the acquisition method (stock options) and a cashless exercise/same-day sale payment, and includes the signature representation that no material nonpublic information is known. The form references Rule 10b5-1 plan adoption or instructions but does not list a plan adoption date in the shown fields.

Given those entries, confirm whether a written trading plan exists and its adoption date if relying on 10b5-1; any plan date would clarify affirmative safe-harbor reliance within the filing record.

FAQ

What does Axsome (AXSM) Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 13,390 common shares via Goldman Sachs & Co. LLC on 10/07/2025 with aggregate market value $1,588,589.60.

How many Axsome (AXSM) shares were sold by the insider in the past three months?

The filing lists four sales totaling 82,100 shares on 09/12/2025, 09/15/2025, 09/16/2025, and 10/06/2025.

Were the shares to be sold by the insider originally acquired as compensation?

Yes. The 13,390 shares were acquired on 05/27/2016 as compensation through stock options and paid by a cashless exercise/same-day sale.

Who is the seller named in the Form 144?

The seller identified for recent sales is Herriot Tabuteau with an address listed in New York, NY.

Does the Form 144 state the filer knows of any undisclosed material nonpublic information?

By signing, the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 04:43 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001219927
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Axsome Therapeutics, Inc.
SEC File Number	001-37635
Address of Issuer	One World Trade Center 29th Floor New York NEW YORK 10007
Phone	1-212-332-3241
Name of Person for Whose Account the Securities are To Be Sold	Herriot Tabuteau
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	13390	1588589.6	49901487	10/07/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	05/27/2016	Acquired as compensation -- Stock Options	The Issuer			13390	05/27/2016	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	10/06/2025	19220	2309661.63
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	09/12/2025	27907	3319894.86
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	09/15/2025	15254	1790378.76
Herriot Tabuteau One World Trade Center 29th Floor New York NY 10007	Common Stock	09/16/2025	19719	2251690.92

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 6/13/2025, that is intended to comply with Rule 10b5-1(c).
Date of Notice	10/07/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/13/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Herriot Tabuteau
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)